News | January 30, 2024
Covestro’s new medical polycarbonate pushes the boundaries of heat resistance
Combines biocompatibility, heat-resistance, transparency and durability
Combines biocompatibility, heat-resistance, transparency and durability
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about US$ 139.43 million
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
The company will be preferred business partner for VPPL in terms of sourcing and supplying key raw materials
Novartis India has reported total income of Rs. 106.50 crores during the period ended December 31, 2023
The company intends to respond to the two minor observations within the stipulated time
Astec LifeSciences has reported total income of Rs. 51.70 crores during the period ended December 31, 2023
Gabapentin is indicated for the management of Postherpetic Neuraligia
Subscribe To Our Newsletter & Stay Updated
